早期子宫内膜癌患者参与式随访:OPAL试验的长期随访
OPAL试验的长期随访比较患者参与式随访(PIFU)与医院随访(HBFU)对早期子宫内膜癌患者的影响。212例I期中低危子宫内膜癌患者随机分组,随访34个月时两组癌症复发恐惧均下降且无差异(差值-6.31,95%CI -14.24至1.63),生活质量各领域无差异,PIFU组医疗使用显著更低(P<0.01)。
要点
- 随访34个月时PIFU与HBFU两组癌症复发恐惧均下降且无差异(差值-6.31,95%CI -14.24至1.63)。
- 随访34个月时两组生活质量各领域无差异。
- PIFU组医疗使用显著低于HBFU组(P<0.01)。
核心结论
- 对于已接受治疗且复发风险低的子宫内膜癌患者,患者参与式随访是医院随访的有效替代方案。
研究设计与样本
- 实用性、多中心随机试验,在丹麦4个妇科科室于2013年5月至2016年5月开展,纳入212例I期中低危子宫内膜癌女性。
主要发现
- 癌症复发恐惧从基线至34个月在两组均下降,两组间无差异(差值-6.31,95%CI -14.24至1.63)。
- 使用线性混合模型分析,34个月时两组生活质量各领域均无差异。
- PIFU组医疗使用显著低于HBFU组(P<0.01)。
关键数值与推荐
- 对照组接受医院随访,初级治疗后3年内定期门诊访视(即8次)。
- 干预组接受患者参与式随访,无预先安排的访视,但提供警报症状说明和自我转诊选择。
临床怎么用
- 原文结论认为患者参与式随访是医院随访的有效替代方案,适用于已接受治疗且复发风险低的子宫内膜癌患者。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A long-term follow-up of the OPAL trial to compare the effect of patient-initiated (PIFU) versus hospital-based (HBFU) follow-up on fear of cancer recurrence (FCR), quality of life (QoL) and healthcare use after 34 months of follow-up. DESIGN: Pragmatic, multicentre randomised trial. SETTING: Four Danish departments of gynaecology between May 2013 and May 2016. POPULATION: 212 women diagnosed with stage I low-intermediate risk endometrial carcinoma. METHODS: The control group attended HBFU with regular outpatient visits (i.e., 8) for 3 years after primary treatment. The intervention group underwent PIFU with no prescheduled visits but with instructions about alarm symptoms and options of self-referral. MAIN OUTCOME MEASURES: The endpoints were FCR as measured by the Fear of Cancer Recurrence Inventory (FCRI) and QoL as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire C-30 (EORTC QLQ C-30), and healthcare use as measured by questionnaires and chart reviews after 34 months of follow-up. RESULTS: FCR decreased from baseline to 34 months in both groups and no difference was found between allocations (difference -6.31 [95% confidence interval -14.24 to 1.63]). QoL remained stable with no difference in any domains between the two arms at 34 months using a linear mixed model analysis. The use of healthcare was significantly lower in the PIFU group (P < 0.01). CONCLUSION: Patient-initiated follow-up is a valid alternative to hospital-based follow-up for people who have been treated for endometrial cancer and have low risk of recurrence.
引用
- Rulanda MC, Mogensen O, Jensen PT, et al. Patient-initiated follow-up in women with early-stage endometrial cancer: A long-term follow-up of the OPAL trial. BJOG. 2023. PMID: 37277320. doi:10.1111/1471-0528.17567
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。